KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Cash & Equivalents (2017 - 2025)

Bionano Genomics (BNGO) has disclosed Cash & Equivalents for 9 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 67.4% to $3.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Dec 2025, down 67.4% year-over-year, with the annual reading at $3.0 million for FY2025, 67.4% down from the prior year.
  • Cash & Equivalents hit $3.0 million in Q4 2025 for Bionano Genomics, down from $3.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $362.1 million in Q1 2021 to a low of $3.0 million in Q4 2025.
  • Historically, Cash & Equivalents has averaged $53.7 million across 5 years, with a median of $15.3 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: surged 4369.84% in 2021 and later tumbled 93.36% in 2022.
  • Year by year, Cash & Equivalents stood at $24.6 million in 2021, then plummeted by 79.28% to $5.1 million in 2022, then soared by 252.54% to $17.9 million in 2023, then tumbled by 48.89% to $9.2 million in 2024, then crashed by 67.4% to $3.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for BNGO at $3.0 million in Q4 2025, $3.1 million in Q3 2025, and $3.6 million in Q2 2025.